These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1109570)

  • 1. Effect of acylation with eleostearic acids on the monoamine oxidase inhibitory potency of some hydrazine antidepressants in mice.
    Hsu SY; Huang CL; Waters IW
    J Med Chem; 1975 Jan; 18(1):20-3. PubMed ID: 1109570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis of some N-substituted eleostearic acid hydrazides as potential monoamine oxidase inhibitors.
    Hsu SY; Huang CL; Waters IW
    J Med Chem; 1973 May; 16(5):450-2. PubMed ID: 4146252
    [No Abstract]   [Full Text] [Related]  

  • 3. Quipazine, a new type of antidepressant agent.
    Rodríguez R; Pardo EG
    Psychopharmacologia; 1971; 21(1):89-100. PubMed ID: 5567294
    [No Abstract]   [Full Text] [Related]  

  • 4. Behavior and biochemical effects of preferentially protecting monoamines in the brain against the action of reserpine.
    Butcher LL; Rhodes DL; Yuwiler A
    Eur J Pharmacol; 1972 May; 18(2):204-12. PubMed ID: 4537669
    [No Abstract]   [Full Text] [Related]  

  • 5. Synthesis and antidepressant activity of 5-phenyl-2-(2-propynylamino)-2-oxazolin-4-one and derivatives.
    Lee CM; Horrom BW; Michaels RJ; Rasmussen RM; Plotnikoff NP
    J Med Chem; 1972 Dec; 15(12):1252-5. PubMed ID: 4635969
    [No Abstract]   [Full Text] [Related]  

  • 6. Antagonism of psychostimulant 2-phenyl-5,5-dimethyl-tetrahydro-1,4-oxazine hydrochloride (G 130) to central nervous system depressing drugs. Monoamine oxidase inhibitory activity and norepinephrine and serotonin induced changes. Comparison with dL-amphetamine.
    Fanelli O; Mazzoncini V; Trallori L
    Arzneimittelforschung; 1974 Dec; 24(12):2025-9. PubMed ID: 4480283
    [No Abstract]   [Full Text] [Related]  

  • 7. L-Dopa and imipramine: biochemical and behavioral interaction.
    Friedman E; Gershon S
    Eur J Pharmacol; 1972 May; 18(2):183-8. PubMed ID: 5037381
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of 4-chlorophenoxyamphetamine (A-6587), d-amphetamine and 4-chloroamphetamine on brain biogenic amines and behavior in mice.
    Everett GM; Yellin TO
    Res Commun Chem Pathol Pharmacol; 1971; 2(4):407-13. PubMed ID: 4400361
    [No Abstract]   [Full Text] [Related]  

  • 9. An analysis of DOPA-induced locomotor stimulation in mice with inhibited extracerebral decarboxylase.
    Przegaliński E; Kleinrok Z
    Psychopharmacologia; 1972; 23(3):279-88. PubMed ID: 4260342
    [No Abstract]   [Full Text] [Related]  

  • 10. [Effect of various antidepressive agents on brain monoamine oxidase activity].
    Gankina EM; Moskvitina TA; Gorkin VZ; Val'dman AV
    Biull Eksp Biol Med; 1982 Nov; 94(11):29-31. PubMed ID: 7150732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of 1-(indolyl-2-carbonyl)-2-alkyl-hydrazine derivatives on amine levels and monoamine oxidase activity in rat tissues.
    Vega P; Borrell S
    Biochem Pharmacol; 1972 Oct; 21(19):2571-5. PubMed ID: 4661618
    [No Abstract]   [Full Text] [Related]  

  • 12. Potentiation and inhbition of some central actions of L(-)-dopa by decarboxylase inhibitors.
    Lotti VJ; Porter CC
    J Pharmacol Exp Ther; 1970 Apr; 172(2):406-15. PubMed ID: 5441162
    [No Abstract]   [Full Text] [Related]  

  • 13. Dopa reversal of reserpine enhancement of audiogenic seizure susceptibility in mice.
    Boggan WO; Seiden LS
    Physiol Behav; 1971 Mar; 6(3):215-7. PubMed ID: 5125476
    [No Abstract]   [Full Text] [Related]  

  • 14. Spinal monoamines and the toxic interaction between monoamine oxidase inhibitors and tricyclic antidepressants.
    Clineschmidt BV
    Eur J Pharmacol; 1972 Jul; 19(1):126-9. PubMed ID: 4403107
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhibition of monoamine oxidase-A activity in rat brain by synthetic hydrazines: structure-activity relationship (SAR).
    Dar A; Khan KM; Ateeq HS; Khan S; Rahat S; Perveen S; Supuran CT
    J Enzyme Inhib Med Chem; 2005 Jun; 20(3):269-74. PubMed ID: 16119198
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Central effects of betamezide].
    Mikhaĭlova TV; Gilev AP; Khavronina-Gureeva ZP
    Farmakol Toksikol; 1969; 32(6):652-6. PubMed ID: 5381593
    [No Abstract]   [Full Text] [Related]  

  • 17. Pharmacologic profile of fezolamine fumarate: a nontricyclic antidepressant in animal models.
    Baizman ER; Ezrin AM; Ferrari RA; Luttinger D
    J Pharmacol Exp Ther; 1987 Oct; 243(1):40-54. PubMed ID: 3668867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-substituted cyclopropylamines as monoamine oxidase inhibitors. Structure-activity relationships. Dopa potentiation in mice and in vitro inhibition of kynuramine oxidation.
    Mills J; Kattau R; Slater IH; Fuller RW
    J Med Chem; 1968 Jan; 11(1):95-7. PubMed ID: 4384132
    [No Abstract]   [Full Text] [Related]  

  • 19. Histochemical fluorescence detection of changes in central monoamine neurones provoked by drugs acting on the CNS.
    Fuxe K; Hökfelt T
    Triangle; 1971; 10(3):73-84. PubMed ID: 5138525
    [No Abstract]   [Full Text] [Related]  

  • 20. [Activity of toloxatone, antidepressive agents and various other reserpine antagonists on three behavior tests, in the mouse treated with nialamide].
    Gouret C; Raynaud G
    Therapie; 1975; 30(2):225-30. PubMed ID: 1080583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.